Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
The LancetOpinion

Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response

The rise of ultra-processed foods (UPFs) in human diets is harming global public health. However, policy responses are still ...
Frontiers

Next-Generation Persuasive Technologies for Human–AI Interaction and Behavior Change

Persuasive technology has evolved from simple behavior-change tools to complex, interactive systems that dynamically adapt to users’ needs, contexts, and ...